GSK press releases Follow Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care. https://www.gsk.com/en-gb/media/press-releases/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma/ gsk.com
